Four studies presented at Neuroscience 2026 reveal that biological sex and genetics influence how neurological disorders develop and respond to treatment.

Mateja Perović at the University of Toronto found that people carrying genetic risk factors for Alzheimer's disease responded differently to menopause hormone therapy compared with those without the same genetic risks. The effects also varied by hormone formulation.

Stephanie M. Perez at the University of Texas Health Science Center at San Antonio studied rodents undergoing menopause with genetic risk factors for Alzheimer's. Brain circuits responsible for memory became particularly vulnerable, suggesting menopause may represent a period of increased susceptibility for women genetically predisposed to the disease.

Yasmin Sahlloul at the University of Cincinnati examined a mouse model of fibromyalgia. Females showed heightened sensitivity to touch and stronger immune system activation compared with males, suggesting chronic pain processes may differ between sexes.

Nurcan Kilic at the University of North Dakota found that chronic gut inflammation affected brain function and Alzheimer's-related disease changes differently in male and female mice.

Liisa Galea, Treliving Family Chair in Women's Mental Health at Centre for Addiction and Mental Health and moderator of the press conference, stated the research "helps us pinpoint the specific differences that may help us develop more targeted treatment using precision approaches, even for some of our most complex brain disorders."